Lunai Bioworks Inc. (LNAI), an AI-driven life sciences company, on Monday announced a $20 million preferred equity issuance to acquire intellectual property to strengthen its platform for developing drug delivery to the central nervous system.
The intellectual property (IP), acquired from to counterparties, will allow for the expansion of the company's central nervous system (CNS) platform, addressing a limitation in drug delivery that crosses the blood-brain-barrier (BBB) for effective treatment of neurological indications like Alzheimer's disease.
The acquired assets will be merged into the company's subsidiary, Lunai Bioworks IP Inc. On May 1, 2026, Lunai issued Series B Preferred Stock worth an aggregate value of $20 million to the Holders, to facilitate the merger.
The acquired IP is expected to contribute to the company's Augusta platform, which stratifies patients according to underlying biological drivers, and will also strengthen biodefense initiatives, like the Pathfinder program.
LNAI is currently trading at $0.36, up 14.72%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.